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1. Introduction
In 1989 Tei et al. developed Waon therapy for heart failure that uses a dry sauna (Tei et
al., 1994; Tei et al., 1995; Tei 2007). Waon therapy means a thermal therapy using special‐
ly designed sauna bath for heart failure. In the therapy, patients were placed in a sitting-
position in a 60 ◦C far infrared-ray dry sauna system for 15 min, and then after leaving
the sauna, they underwent bed rest with a blanket to keep them warm for an additional
30 min. And fluids corresponding to perspiration are supplied to protect against dehydra‐
tion at the end of therapy. In this specially designed sauna system, the body core temper‐
ature has increased by 1.0–1.2°C, various beneficial effects for symptoms of heart failure
were found (Tei, 2007).
Tei  et  al.  have  reported  that  Waon  therapy  significantly  improved  clinical  symptoms,
increased  ejection  fraction,  and  decreased  cardiac  size  on  echocardiography  and  chest
radiography  in  congestive  heart  failure  (CHF)  patients  (Tei  &  Tanaka,  1996).  Recently,
Miyata M et al. confirmed the beneficial effects and safety of Waon therapy applied for 2
weeks  in  CHF  patients  in  a  prospective  multicenter  case—control  study  (Miyata  et  al.,
2008). Kihara et al. previously demonstrated that Waon therapy improved not only cardiac
function, but also endothelial function in patients with CHF. They have also reported that
2 weeks of Waon therapy significantly reduced brain natriuretic peptide blood levels and
improved flow-mediated vasodilation in CHF patients (Kihara et al.,  2002). Furthermore,
they  have  reported  that  Waon  therapy  for  2  weeks  decreased  ventricular  premature
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contractions  and  increased  heart  rate  variability  in  CHF  patients  (Kihara  et  al.,  2004),
suggesting  that  Waon  therapy  decreased  sympathetic  nervous  activity  and  improved
ventricular arrhythmias.
A  large  number  of  end-stage  CHF  patients  in  Japan  have  been  implanted  with  a  left
ventricular  assist  device  (LVAD)  because  of  prolonged  waiting  period  for  heart  trans‐
plants (Osada et al., 2005). Although we wished to apply sauna thermal therapy to patients
with LVAD, we do not have an appropriate sauna facility. Thus, we attempted to apply
lower  leg  thermal  therapy  to  the  patients  with  LVAD  awaiting  a  heart  transplant.  We
describe here a case series of lower leg thermal therapy for the first time to elucidate the
safety and effectiveness of this preliminary trial for the patients fitted with left ventricu‐
lar assist device for end-stage heart failure.
2. Methods
2.1. Patients and study design
The study subjects included consecutive 6 end-stage CHF patients who were listed on waiting
list for heart transplant in National Cerebral and Cardiovascular Center, Suita, Japan. All
patients had dilated cardiomyopathy refractory to maximal medical therapy including
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers,
diuretics, and digitalis. Regardless of intensive care with intravenous inotropic agents, heart
failure rapidly progressed to cardiogenic shock in the patients. And they were fitted with
extracorporeal LVAD (VCT-50, Toyobo Ltd., Osaka, Japan) to stabilize the hemodynamics.
None of the patients was implanted with a defibrillator device.
Patients’ general condition stabilized thereafter and the status of heart failure at the time of
study was New York Heart Association (NYHA) class IIm with hemodynamic support.
Although this status remained stable for at least 6 months, patients’ cardiac function did not
sufficiently recover to discontinue LVAD support. The patient provided written informed
consent to enter into a clinical trial of lower leg thermal therapy for patients with LVAD
awaiting a heart transplant. The Ethics Committee at the National Cerebral and Cardiovascular
Center approved the protocol, and the study was conducted in accordance with the Declaration
of Helsinki. Lower leg thermal therapy was conducted with a steam bath at 42 ◦C. Typical
example of lower leg thermal therapy was illustrated in Fig.1.
After 15 min of therapy at 42 ◦C, the patient remained seated in the steam bath with the lower
legs and feet wrapped with a blanket for 30 min. The study consisted of clinical examinations
before and after daily thermal therapy for 2 weeks (Fig. 2).
Study protocol for 2 weeks treatment was illustrated in Fig. 3. The procedure of lower leg
thermal therapy was accompanied by electrocardiographic monitoring. The patient remained
on the same medications with same dose throughout the study period.
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Figure 1. Typical settings for lower leg thermal therapy for a patient with left ventricular assist device.
Figure 2. Illustrative presentation of the lower leg thermal therapy.
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Figure 3. Illustrative presentation of the study design of lower leg thermal therapy.
2.2. Measurements
Systolic and diastolic blood pressure (BP), heart rate, body weight, surface and deep body
temperature (axillary and sublingual) were measured everyday throughout the study. Chest
X-ray, ambulatory electrocardiogram, echocardiogram and peripheral arterial tonometry were
recorded and blood sampling was taken before and 2 weeks after the treatment. Blood
sampling was used for measurement of plasma BNP, plasma nitrates and nitrites, plasma
hydroperoxides, and HClO expense test.
Medical interview was done every morning to evaluate clinical status of CHF by NYHA
functional class, and to estimate patients’ activity of daily life using Specific Activity Scale
(SAS). We used the Specific Activity Scale as a measure of quality of life (QOL) in which self-
perceived exercise tolerance is expressed by an energy cost spent in the maximal physical
activity that the patient can perform (Sasayama et al., 1992). The Specific Activity Scale allows
expression of the extent of submaximal physical activity. Sasayama et al. actually measured
the metabolic costs of various types of physical activity by hooking subjects up to a mask to
measure oxygen consumption and the volume of carbon dioxide exhaled. Then they prepared
questionnaires about specific physical activities that a patient would perform either custom‐
arily or sporadically in daily life and each patient was asked to specify whether he/she could
perform each type of activity without symptomatic limitation. Summarizing the questionnaire
data, a given number of metabolic costs (Specific Activity Scale) were derived for each patient
with regard to the self-perceived exercise tolerance. As a clear linear correlation was observed
between Specific Activity Scale and peak oxygen consumption, the Specific Activity Scale was
considered to reliably predict exercise capacity (Sasayama et al., 1992)
Before and 2 weeks after the treatment, the cardiothoracic ratio (CTR) was measured by chest
radiography and daily count of ventricular premature beats was evaluated with ambulatory
electrocardiogram. Before and 2 weeks after the treatment, two-dimensional echocardiogra‐
phy were performed to determine left ventricular systolic (LVDs) and diastolic dimension
(LVDd), left atrial dimension (LAD), LV fractional shortening and degree of mitral regurgitation.
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Venous blood samples were drawn through an indwelling catheter in the forearm of each patient
after they had lain quietly and undisturbed for at least 30 min. Plasma was immediately separated
and stored at –70°C before the norepinephrine (NE) concentrations were determined by high
performance  liquid  chromatography  electrochemical  detection.  Plasma  brain  natriuretic
peptide (BNP) was determined by the chemiluminescent enzyme immunoassay. For nitric oxide
(NO) measurement, the blood specimen was placed immediately in an ice bath and centri‐
fuged within 30 seconds for 5 minutes at 2000g. The serum fraction was diluted 1:1 with nitrite-
and nitrate-free distilled water, and 400 mL of the diluted sample was centrifuged at 2000g in an
ultra-free MC microcentrifuge device (Millipore) to remove substances larger than 10 kD. The
filtrate was passed through a copper-plated cadmium column to reduce nitrate to nitrite and
then reacted with Griess reagents consisting of 0.1% naphthylethylenediamine dihydrochlor‐
ide in distilled water and 1% sulfanilamide in 5% H3PO4, after which absorbance was meas‐
ured at 540 nm to provide the total amount of plasma NO end products (nitrate plus nitrite). The
efficiency of the cadmium column in the conversion of nitrate to nitrite was confirmed to be 100%
by measuring both nitrate and nitrite standards before and after sample measurement (Node et
al., 1997). Plasma hydroperoxides, which was determined by Diacron reactive oxygen metabo‐
lites test, comprise a marker of oxidative stress (Cesarone et al., 1999) and OXY absorbent test
indicates buffering potential against oxidant action of hypochlorous acid (HClO), which is
quantified by HClO expense, and comprise a marker of anti-oxidative potency (Trotti et al., 2001).
Endothelial function was quantified by the reactive hyperemic (RH) change in digital blood flow
after arm occlusion using a peripheral fingertip arterial tonometry (PAT) device (Endo-PAT 2000
system; Itamar-Medical, Caesarea, Israel) (Bonetti et al., 2004; Hamburg & Benjamin, 2009). After
5 min of baseline recording, a BP cuff was inflated to supra-systolic pressure in the test arm. After
5 min of occlusion, the cuff was rapidly deflated, with PAT tracings recorded. The reactive
hyperemic PAT (RH-PAT) response was determined as the ratio of PAT amplitude in the test
arm to control arm, averaged in 30-s intervals after cuff deflation, divided by the average PAT
ratio measured for the 140-s interval before cuff inflation. RH-PAT ratio was assessed between
60 s and 120 s after occlusion and was log-transformed of the post-deflation to baseline pulse
amplitude in the hyperemic finger normalized to the contralateral finger.
2.3. Statistical analysis
All data are expressed as the mean value±S.D. Differences between the baseline and 2 weeks
after treatment were estimated by paired t test or Mann–Whitney U test, as appropriate for
continuous variables, and by Fisher’s exact test or chi square test, as appropriate for categorical
variables. Value of BNP was log-transformed to remove skewness of data distribution. A p-
value of <0.05 was considered statistically significant.
3. Results
3.1. Clinical findings and physical examinations
Table 1 summarized the results of clinical findings and physical examinations. During the
study, none of the patients treated with lower leg thermal therapy had worsened clinical
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symptoms. The changes in the clinical findings and variables after 2 weeks are summarized
in Table. Although NYHA functional class remained similar at class IIm, activity of daily life
estimated by SAS system significantly increased from 2.55 Mets to 3.10 Mets (p = 0.044).
Systolic and diastolic blood pressure did not differ between the baseline and 2 weeks after the
therapy. Heart rate might tend to decrease a little bit from 74 bpm to 72 bpm (p = 0.088).
Numbers of ventricular premature beats were dispersed among the patients at the baseline as
well as 2 weeks after treatment. Thus, the average number of ventricular premature beats was
not different between the baseline and 2 weeks after the therapy.
There was no significant change in body weight. Body surface temperature (axillary temper‐
ature) in the morning round was not different between the baseline and 2 weeks after the
therapy. However, the deep body temperature (sublingual temperature) significantly in‐
creased from 36.0 degree Celsius to 36.9 degree Celsius (p = 0.004), just after the steam bath for
lower legs. The average difference between the baseline and immediately after the therapy
was 0.85 degree Celsius.
Before After p value
Sample size 6 6
Age (years) 34.8±8.0
Activity of Daily Life (Mets) 2.55±0.81 3.10±0.99 0.044
Systolic BP (mmHg) 91.2±10.0 92.3±14.4 0.682
Diastolic BP (mmHg) 54.8±9.0 56.8±9.2 0.310
Heart Rate (bpm) 74.0±8.3 71.9±8.3 0.088
Ventricular Premature Beats (per day) 92.8±48.1 55.3±15.9 0.100
Body Weight (kg) 53.2±8.9 53.0±9.2 0.383
Morning Body Temperature (C) 35.8±0.33 36.0±0.41 0.476
Deep Body Temperature (C) 36.0±0.26 36.9±0.36 0.004
Cardiothoracic Ratio (%) 56.6±13.2 55.3±13.7 0.065
NE (pg/mL) 971.2±403.6 848.6±313.5 0.077
log BNP (pg/mL) 2.128±0.516 2.080±0.505 0.030
Νitrogen oxide (μmol/L) 30.1±12.1 46.5±17.7 0.019
Hydroperoxides (carr U) 513.0±75.0 439.3±78.4 0.0001
OXY absorbent test (μmol HCl/mL) 400.7±38.2 456.7±51.9 0.078
LAD (mm) 43.3±9.4 41.9±9.5 0.063
LVDd (mm) 54.4±10.8 53.1±11.9 0.130
LVDs (mm) 43.2±13.6 40.3±13.8 0.025
LV Fractional Shortening (%) 21.9±8.7 25.3±8.9 0.028
Mitral Regurgitation (grade) 2.2±1.0 1.3±0.8 0.061
RH-PAT ratio 1.36±0.22 2.09±0.28 0.006
BNP brain natriuretic peptide, BP blood pressure, LAD left atrial dimension, LV left ventricular, LVDd left ventricular
diastolic diameter, LVDs left ventricular systolic diameter, NE norepinephrine, OXY oxidant, RH-PAT reactive hyperemic
peripheral arterial tonometry
Table 1. Summary of changes in parameters before and after the thermal therapy
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3.2. Chest radiography and echocardiography
Table 1. described the results of chest radiography and echocardiography. Chest radiography
showed a slight decrease of the mean CTR from 57% to 55% after 2 weeks of treatment
compared to the baseline (p = 0.065).
Echocardiography demonstrated a slight decrease in the mean LAD from 43 mm to 42 mm (p
= 0.063). While, LVDd showed no changes after treatment (54 mm to 53mm, p = 0.130), LVDs
significantly decreased after treatment from 43 mm to 40 mm (p = 0.025). Therefore, LV
fractional shortening also significantly increased after treatment from 22% to 25% (p = 0.028).
Doppler echocardiography demonstrated that the extent of mitral regurgitation tended to
decrease after treatment (mean MR grade: 2.2 to 1.3, p = 0.061). Taken together, the left
ventricular function was improved and the heart size tended to decrease after 2 weeks of the
therapy.
3.3. plasma levels of norepinephrine, BNP, nitrogen oxide and hydroperoxides, and result
of OXY adsorbent test
Table 1. showed the changes in plasma concentration of norepinephrine, BNP, nitrogen oxide
(nitrate plus nitrite), hydroperoxides and hypochlorous acid. Plasma mean concentration of
norepinephrine slightly decreased after 2 weeks of the therapy (971 pg/mL to 849 pg/mL, p =
0.077). The plasma mean concentration of BNP significantly decreased after 2 weeks of the
therapy, (log BNP: 2.128 to 2.080 pg/mL, p = 0.030).
Plasma mean concentration of nitrogen oxide (nitrate plus nitrite), stable metabolites of nitric
oxide, significantly increased after 2 weeks of the therapy (30.1 μmol/L to 46.5 μmol/L, p =
0.019). Plasma mean concentration of hydroperoxides, a biomarker reflects oxidative stress,
significantly decreased after 2 weeks of the therapy (513 carr U to 439 carr U, p = 0.0001). OXY
absorbent test, a marker of anti-oxidative potency, showed non-significant increase after 2
weeks of the therapy (401 μmol HClO/mL to 457 μmol HClO/mL, p = 0.078)
3.4. Endothelial function
The mean RH-PAT ratio determined with Endo-PAT 2000 system was augmented 2 weeks
after the therapy compared to the baseline (1.36 to 2.09, p = 0.006).
4. Discussion
This is the first report of case series of lower leg thermal therapy being applied to patients
implanted with LVAD and awaiting heart transplantation. Waon therapy or whole body
sauna therapy for CHF is now widely recognized to improve clinical symptoms, cardiac
function,  quality of  life,  and ventricular arrhythmia,  and decreased levels of  abnormally
activated neurohumoral factors (Tei et  al.,  1995;  Tei & Tanaka, 1996;  Tei 2007;  Kihara et
al., 2002; Kihara et al., 2004).
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Waon therapy is impractical for patients with CHF in usual general hospitals that lack sauna
facilities, whereas lower leg thermal therapy using a steam bath can be applied routinely in a
patient’s room in common general hospitals. Increases in deep body temperature of 1.0-1.2 ◦C
during Waon therapy dilate systemic arteries and veins, and reduce systemic preload and
afterload, resulting in increased cardiac output (Tei et al., 1995; Tei & Tanaka, 1996; Tei 2007;
Kihara et al., 2002; Kihara et al., 2004). The sublingual temperature of the patients after our
lower leg thermal therapy increased by only 0.85 ◦C. Nevertheless, the clinical benefits seemed
to be similar to those of Waon or whole body sauna therapy.
Ikeda et al. found that repeated Waon therapy increases endothelial nitric oxide synthase
expression and nitric oxide production, and improves cardiac function in animal models of
heart failure (Ikeda et al., 2001; Ikeda et al., 2005). Serum nitrate plus nitrite levels doubled in
our patient compared with the baseline values, as did the index of endothelial function
determined by RH-PAT. Thus, lower leg thermal therapy might upregulate nitric oxide
production in the endothelium.
Recently, Kuwahata et al. demonstrated that Waon therapy suppressed the elevated auto‐
nomic nervous activity levels in chronic heart failure (Kuwahata et al., 2011). Fujita et al.
reported that Waon therapy reduced oxidative stresses in chronic heart failure (Fujita et al.,
2011). Those findings dovetail with the results of the present study. Lower leg thermal therapy
may have a stress-reducing effect.
Bating in hot water might supress oxidative stress and enhance endothelial  function via
upregulation of expression of heat shock protein (Okada M et al., 2004). Immersion not in
hot water but in warm water (33-34 ◦C) still  ameriorated cardiac dysfunction of chronic
heart failure (Cider A et al.,  2006). Thus, heating may have a beneficial effects on symp‐
toms of heart failure.
Patients implanted with an LVAD for a long period often develop serious hemorrhage in the
cerebrum or elsewhere, and drive-line infections. We were concerned that lower leg thermal
therapy would aggravate hemorrhage or infection of patients through its vasodilatory effects.
On the contrary, we found that oozing of blood at the insertion site of the LVAD drive-line
tended to resolve during the therapy in several patients (data not shown). Furthermore a
previous study reported that topical thermal therapy was not expected to be accompanied by
marked alterations in heart rate, mean arterial pressure, or cardiac output and therefore would
not likely activate the renin-angiotensin aldosterone system (Weber AA et al., 2007). In our
present study, we did not find significant changes in hemodynamics of the patients.
Impacts  of  lower  leg  exercise  on  muscles  and  vessels  of  lower  extrimities  ameriolates
dyspnea in CHF or chronic obstructive pulmonary disease (Beniaminovitz A et al.,  2002;
Sillen MJ et al., 2009). And lower leg exercise increased endothelial function even in upper
armes and affected clinical symptoms of CHF especially in those who cannot do conven‐
tional excercise programme (Deftereos S et al., 2010). Excercise in CHF enhances not only
endothelial functions in systemic vasculature but also has anti-inflammatory effects on the
endothelium (Duscha BD et al., 2008).
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Aside from exercise, heat is a natural vasodilator. Thus, judicious use of heat in the form of
thermal baths, saunas, and/or heating pads is slowly gaining recognition as a potential
supplement to pharmaceuticals to improve endothelial function and cardiorenal hemody‐
namics in selected patients with CHF. Yoon et al. reported that warm footbath increased
coronary blood flow velocity in the left anterior descending coronary artery by 17% in patients
with coronary artery disease (CAD) (Yoon SJ et al., 2011). In our experiment, coronary blood
flow velocity in the left anterior descending coronary artery before and after the lower leg
thermal therapy was determined in a patient with CHF and the velocity increased by 10% after
the therapy (data not shown).
We did not conduct lower leg thermal therapy for CAD patients yet. Previous studies showed
the thermal therapy for CAD might cause myocardial ischemia (Giannetti N et al., 1999), or
myocardial infarction and sudden cardiac death (Hannuksela ML et al., 2001). Thus, CHF due
to non-ischemic diseases like dilated cardiomyopathy in our case might be a good indication
for lower leg thermal therapy.
Waon therapy attenuates psychological stress (Kihara et al., 2004). Because of a donor shortage
in Japan, patients must remain attached to an LVAD and stay for over 2 years in hospital while
waiting for a heart transplant (Takatani et al., 2005). The tendency of decrease in plasma
norepinephrine in the present study indicated that lower leg thermal therapy also might
attenuate psychological, as well as physical stress.
Compared to pharmacological vasodilator therapy and other non-pharmacological therapy,
such as cardiac resynchronization therapy (CRT) or cardiac rehabilitation, there are several
advantages of lower leg thermal therapy for CHF. First, it is quite safe and has no adverse
effects. Second, it might be less expensive and more cost-effective compared to Waon therapy
or CRT. Third, unlike cardiac rehabilitation, patients who have severe congestive heart failure,
uncontrolled ventricular arrhythmias, or orthopedic limitations are not exempt from under‐
going lower leg thermal therapy. Fourth, this treatment may promote mental and physical
relaxation. Above all, the most distinctive feature of lower leg thermal therapy is a potential
to be useful in conjunction with other therapeutic modalities of pharmacological and non-
pharmacological measures. Lower leg thermal therapy may thus be a valuable adjunct to
pharmacological or non-pharmacological intervention in the management of CHF. We have a
high expectation for the future of lower leg thermal therapy. All that we need is a randomized
clinical trial.
5. Study limitation
Although the present study is just preliminary one, sample size is very small, and is not
randomized. Recruitment of study subjects is still continuing. In the present protocol, study
subjects were implanted with LVAD for end-stage heart failure, who were not common in
usual hospitals. Furthermore, the endpoints are surrogate ones. Thus, we have to be very
careful to interpret the study results.
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6. Conclusion
Although in a very small cohort, we confirmed that lower leg thermal therapy was quite safe,
and improved clinical symptoms and cardiac function in patients with extracorporeal LVAD
awaiting heart transplantation. Lower leg thermal therapy may be a valuable adjunct to
pharmacological or non-pharmacological intervention in the management of chronic heart
failure. The procedure of lower leg thermal therapy might benefit other kinds of patients,
including those with end-stage heart failure.
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